In the UK and Europe, the algorithm secured the CE-Mark approval, along with the US Food and Drug Administration (FDA) clearance. The technology is expected to be deployed in the US later this year.

behold.ai chairman and chief executive Simon Rasalingham said: “Our technology has been proven to rapidly diagnose chest X-rays as ‘normal’ or ‘abnormal’ accurately, potentially allowing for faster diagnosis of individuals with Covid-19 and the better management of resources in healthcare systems already stretched by the increase in hospital admissions.

“If successful, this infinitely scaleable pilot programme could make a significant difference to hospitals across India and the rest of the world struggling to manage the Covid-19 pandemic.”

As a result of COVID-19, do you think that telehealth and virtual care technology adoption and usage will remain a staple of the healthcare sector after the pandemic has subsided?

Yes, and adoption and usage will continue to increase

Yes, but adoption and usage will slow down

No, the adoption and usage will only remain high during the COVID-19 pandemic

As part of the pilot programme, the algorithm will also be implemented at certain domestic government-run hospitals in the country.

Apollo Radiology International CEO Dr Sreenivasa Raju Kalidindi said: “Radiology reporting for Covid-19 has to be easily accessible, quick and accurate so that immediate decisions can be made on the next steps. To achieve these goals, Apollo Radiology International is setting up a dedicated centralised Covid-19 reporting service.

“Behold.ai’s chest X-ray algorithm will be an important component of this service. The instant triage provided by this algorithm will be a key factor that will allow our radiologists to provide immediate reports for these patients.”

RECOMMENDED COMPANIES

Learn more

Hover over the logos to learn more about the companies who made this project possible.

Finnomedo

About

Finnomedo has launched a novel product for staunching haemorrhage. The most characteristic feature of this pressure dressing is that it is fully transparent. FinnoPress® has multiple advantages compared with regular pressure bandages, such as visibility to the trauma and foolproof and secure placement.

Make an Enquiry

Finnomedo has launched a novel product for staunching haemorrhage. The most characteristic feature of this pressure dressing is that it is fully transparent. FinnoPress® has multiple advantages compared with regular pressure bandages, such as visibility to the trauma and foolproof and secure placement.